Bristol-Myers Slips Suit Over $6.4B Investor Payment, For Now
By Lauren Berg · March 1, 2023, 10:43 PM EST
A Manhattan federal judge Wednesday dismissed a proposed class action alleging Bristol-Myers Squibb Co. and its executives intentionally delayed the U.S. Food and Drug Administration's approval of a cancer treatment developed...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login